Pulmonary Drugs Market 2028 By Drug Class, Application, Distribution Channel and Geography | The Insight Partners

report image

Pulmonary Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Others); Application (Asthma and COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00003538 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

[Research Report]


Pulmonary drugs are used to treat a variety of conditions that affect the lungs. The pulmonary drugs category includes medications for a wide range of diseases, from the common cold to long-term chronic disorders like COPD and asthma. The pulmonary drugs are available in various dosage forms that include, oral tablets, inhalers , liquids, injections and others. The key driving factors for the pulmonary drugs market are, increasing prevalence of pulmonary and respiratory diseases like, COPD, asthma, cystic fibrosis along with new product launches and drug approvals.


The "Global Pulmonary Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the pulmonary drugs market with detailed market segmentation by drug class, application and distribution channel. The report provides key statistics on the market status of the leading pulmonary drugs market players and offers key trends and opportunities in the market.


  •   Based on drug class the market is segmented as, inhaled corticosteroids, long acting beta-2 agonists, antihistamines, vasodilators, short acting beta-2 agonists, and others.
  •   Based on application the market is segmented as, asthma & COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others.
  •   Based on distribution channel the market is segmented as, hospital pharmacies, retail pharmacies, and online pharmacies.



  •   Increasing prevalence of pulmonary and respiratory diseases like, COPD, asthma, cystic fibrosis along with new product launches and drug approvals.
  •   Risk factors such as, smoking, unhealthy lifestyles, genetic factors.
  •   Growing R&D investments to develop more prominent therapies for management of pulmonary disorders.


  •   However, side effects associated with the prolonged use of pulmonary drugs is expected to restrain market growth during the forecast period.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The pulmonary drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the pulmonary drugs market in these regions.


COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities. Majority of pharmaceutical and biopharmaceutical companies are engaged in development of prominent therapies for COVID-19 and this significantly affecting market for pulmonary drugs. But in some instances, few pulmonary drugs are helpful in management of COVID- 19 infection as it affects the lungs. So some pulmonary agents are used to manage the symptoms.


The report covers key developments in the pulmonary drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from pulmonary drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for pulmonary drugs in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the pulmonary drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Sanofi
  •   Viatris Inc
  •   Circassia
  •   AstraZeneca
  •   GlaxoSmithKline Plc
  •   Mallinckrodt
  •   CHIESI Farmaceutici S.p.A
  •   Zambon
  •   Novartis AG
  •   Merck Sharp and Dohme Corp
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The List of Companies

- Sanofi
- Viatris Inc
- Circassia
- AstraZeneca
- GlaxoSmithKline Plc
- Mallinckrodt
- CHIESI Farmaceutici S.p.A
- Zambon
- Novartis AG
- Merck Sharp and Dohme Corp
- Teva Pharmaceutical Industries Ltd
- Cipla Inc.
- Sun Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd
- Glenmark Pharmaceutical Inc., USA
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount